VEGF and p53 Biomarkers in Pediatric Patients With Langerhans Cell Histiocytosis

Mehrazma, Mitra; Mahjoob, Fatemeh; Ka, Rafsanjani; Jafari, Daniel; Sj, Farahani; Lahouti, H A

doi:10.1097/mph.0b013e31828e51ae

Cited by 3 publications

(2 citation statements)

References 21 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Canine cutaneous histiocytoma is usually unique, without a tendency for metastasis and with a favorable prognosis (1). Moreover, our results could emphasize the importance of VEGF as a therapeutic target during the early phases of malignancy in humans by inhibiting tumoral angiogenesis and early invasion of malignant cells (26,28).…”

Section: Discussionmentioning

confidence: 54%

See 1 more Smart Citation

A Role for Angiogenesis in Canine Cutaneous Histiocytoma Regression: Insights into an Old Clinical Enigma

Costa

Ferreira

Prada

et al. 2020

In Vivo

View full text Add to dashboard Cite

Background/Aim: Canine Cutaneous Histiocytoma (CCH) is a Langerhans' cells benign tumour that undergoes spontaneous regression. The aim of the present study was to investigate the role of angiogenesis, a key step for tumour development, in CCH regression. Materials and Methods: 50 CCH samples were classified into 4 histological groups according to a regression scale, and evaluated for expression of vascular endothelial factor-A (VEGF-A) and its receptor VEGFR-2 as well as microvessel density (MVD). Results: Tumours during early stages of the regressive process had a lower MVD compared to later stages, while CCH tumoural cells showed a limited production of VEGF, but higher levels of VEGFR-2. On the contrary, tumours in advanced phases of regression showed a higher number of neovessels, probably associated with the inflammatory state and the healing process. Conclusion: Our results suggest that angiogenesis may be compromised at early stages of histiocytoma development and this may be a determinant of regression in this tumour.Canine cutaneous histiocytoma (CCH) is a benign tumour on the dog's skin that, in almost all cases, undergoes spontaneous regression. It can occur anywhere on the dog's skin surface as 3279 This article is freely accessible online.

show abstract

Section: Discussionmentioning

confidence: 54%

“…Our results are not similar to studies about angiogenesis in Langerhans cells human histiocytosis. These tumour cells express VEGF especially in disseminated lesions (26)(27)(28). This could be justified partially by the distinct clinic behavior and aggressiveness of these tumors when compared to canine cutaneous histiocytoma.…”

Section: Discussionmentioning

confidence: 99%

A Role for Angiogenesis in Canine Cutaneous Histiocytoma Regression: Insights into an Old Clinical Enigma

Costa

Ferreira

Prada

et al. 2020

In Vivo

View full text Add to dashboard Cite

show abstract

p53 Is a Helpful Marker in Distinguishing Langerhans Cell Histiocytosis From Langerhans Cell Hyperplasia

Grace

Sutton

Armbrecht

et al. 2017

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Langerhans cell histiocytosis (LCH) is a proliferative disorder of Langerhans cells that can be challenging to distinguish histologically from Langerhans cell (LC) hyperplasia, seen in a variety of inflammatory dermatoses. Lesional cells in both entities demonstrate positive staining for CD1a and S100. Previous studies have demonstrated positive staining of fascin, CD31, and p53 in cases of LCH, but currently, no studies have compared the staining profiles of these markers between LCH and LC hyperplasia. The authors compared immunohistochemical staining profiles of LCH (n = 15) and various inflammatory dermatoses with LC hyperplasia (n = 15) using fascin, CD31, and p53. Fascin, CD31, and p53 were graded as a percentage of CD1a staining cells in the epidermis and dermis of each specimen. Fascin showed no significant differences in staining between the 2 entities. CD31 was positive in the dermal infiltrate in 40% of cases of LCH and negative in all cases of LC hyperplasia. p53 was positive in the epidermal infiltrate in 50% of cases of LCH, and positive in the dermal infiltrate in 93% of cases of LCH, whereas negative in all cases of LC hyperplasia. Fascin was not a helpful marker in distinguishing LCH from LC hyperplasia. CD31, if positive in the dermal infiltrate, is suggestive of a diagnosis of LCH, but exhibits a relatively low sensitivity for this purpose. p53 proved to be a helpful and accurate diagnostic immunohistochemical stain when distinguishing between LCH and LC hyperplasia.

show abstract

CyclinD1 Is Useful to Differentiate Langerhans Cell Histiocytosis From Reactive Langerhans Cells

Chatterjee¹,

Vishwajeet²,

Saikia³

et al. 2019

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Langerhans cell histiocytosis (LCH) is a rare histiocytic disorder characterized by clonal proliferation of neoplastic Langerhans cells (LCs). LC proliferation can also be seen in different reactive dermatosis. CyclinD1 is a downstream marker of mitogen-activated protein (MAP) kinase pathway, which is often activated in LCH. This study aimed to evaluate the role of cyclinD1 to differentiate reactive LC proliferation from LCH. All cases of cutaneous LCH diagnosed by biopsy in the past 3 years (n = 13) were immunostained with CD1a, p53, CD31, and cyclinD1. Seven cases each of discoid lupus erythematosus (DLE) and lichen planus (LP) were taken as control. Presence of p53, CD31, and cyclinD1-positive LCs (CD1a-positive) were compared in the dermis. In all LCH cases, dermal neoplastic LCs showed diffuse CD1a positivity and 12 cases (92.3%) showed variable (30%-70%) cyclinD1 expression. Weak p53 and CD31 expression were seen in 61.5% and 46.1% of LCH cases, respectively. In the control group, 5 cases of LP and 4 cases of DLE showed variable LC proliferation, highlighted by CD1a positivity. However, no case of reactive dermatosis showed cyclinD1 or p53 expression by the reactive LCs. Weak and patchy CD31 expression by the reactive LCs were found in 1 (25%) and 2 (40%) cases of DLE and LP, respectively. To conclude, cyclinD1 is frequently expressed in neoplastic LCs in LCH. It is an efficient marker to differentiate neoplastic from reactive LC proliferation, and can be used as a surrogate marker in LCH.

show abstract

VEGF and p53 Biomarkers in Pediatric Patients With Langerhans Cell Histiocytosis

Abstract: These findings highlight the role of angiogenic factors in the clinical behavior of LCH and might be of prognostic or therapeutic importance. However, further studies, with larger sample sizes are warranted.

Cited by 3 publications

References 21 publications

A Role for Angiogenesis in Canine Cutaneous Histiocytoma Regression: Insights into an Old Clinical Enigma

A Role for Angiogenesis in Canine Cutaneous Histiocytoma Regression: Insights into an Old Clinical Enigma

p53 Is a Helpful Marker in Distinguishing Langerhans Cell Histiocytosis From Langerhans Cell Hyperplasia

CyclinD1 Is Useful to Differentiate Langerhans Cell Histiocytosis From Reactive Langerhans Cells

Contact Info

Product

Resources

About